Enzalutamide (Xtandi) in combination with leuprolide acetate produced a significant benefit in terms of overall survival (OS) vs leuprolide acetate alone for the treatment of patients with high-risk, biochemically recurrent prostate cancer,…
Enzalutamide Plus Leuprolide Yields OS Benefit in High-Risk, Biochemically Recurrent Prostate Cancer,
